Navigation Links
Power Morcellator Cancer Risk Prompts UPMC to End Uterine Morcellation, Bernstein Liebhard LLP Reports
Date:8/5/2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- The cancer risk associated with power morcellators (http://www.injurybeacon.com/power-morcellator/) has prompted one large healthcare provider to suspend minimally-invasive uterine surgeries that require the use of such devices, Bernstein Liebhard LLP reports.  According to an August 1st report from the Pittsburgh Business Times, a spokesperson for Pennsylvania-based UPMC confirmed the decision last Friday, stating that the move was an "appropriate and prudent course of action" while the hospital network awaits further guidance from the U.S. Food & Drug Administration (FDA).

"UPMC's decision to suspend uterine morcellation is not surprising in light of the recent evidence linking the using of power morcellators to the spread of uterine cancers," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free morcellator lawsuit reviews to women who may have experienced the spread of undiagnosed uterine sarcoma and other cancers due to uterine morcellation.

Morcellator Cancer Risk

Power morcellators are used during laparoscopic hysterectomies and fibroid removals to shred tissue in order to facilitate its removal through a small abdominal incision. On April 17th, the FDA warned that power morcellators have the potential to spread undetected uterine cancer cells into a woman's peritoneal cavity, upstaging the cancer and greatly reducing the patient's chances for long-term survival. According to the agency, roughly 1 in 350 women with fibroids actually have undiagnosed uterine sarcoma.

On July 22nd, the Journal of the American Medical Association published a study that appeared to confirm this risk in both older women, as well as those under the age of 50. Days later, Johnson & Johnson's Ethicon Inc. unit announced a power morcellator recall for three devices marketed by the company, stating that the risks and benefits associated with uterine morcellation were uncertain.

On August 1st, Pennsylvania-based Highmark Inc., one of the nation's largest Blue Cross and Blue Shield insurance providers, announced it would no longer cover uterine morcellation as of September 1st. According to the Pittsburgh Business Times, Highmark also owns the West Penn Allegheny Health System, which along with UPMC, is one of the major healthcare providers in Western Pennsylvania. As such, uterine morcellation is about to become largely unavailable in the Pittsburgh area.

Alleged victims of uterine sarcomas and other cancers spread via a power morcellator may be eligible to file a morcellator lawsuit against the manufacturer of the device used in their surgery. To learn more about the risks potentially associated with uterine morcellation, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling (888) 340-4807.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com 
www.injurybeacon.com
https://plus.google.com/115936073311125306742?rel=author

Logo - http://photos.prnewswire.com/prnh/20120202/MM47134LOGO

 


'/>"/>
SOURCE Bernstein Liebhard LLP
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
2. ResearchMoz: Global Power Wheelchairs Market Will Reach $3.9 Billion by 2018 - Market Research Report
3. Effectiveness of Medicare Authorization Program for Power Wheelchairs Rests on Inclusion of a Clinical Template
4. The Healing Power of Human Milk
5. Kaiser Permanente Ranks Highest in 2012 J.D. Power and Associates Employer Satisfaction Study for Second Year in a Row
6. Providers of Durable Medical Equipment Ensure Independence and Safety during Extreme Weather and Power Outages
7. Physician Details Problems with Medicare Approval Process for Power Wheelchairs
8. Power Wheelchair Brings Independence and Hope to Man with Complications Due to Spina Bifida
9. American Association for Homecare Expects Medicare to Move Past its Deny-at-All-Costs Culture that Routinely Denies Claims for Power Wheelchairs
10. The Princess Margaret BMT Program Chooses Remedy Informatics Blood and Marrow Transplant & Cell Therapy Solutions to Power their fight Against Cancer
11. Henry Schein Announces Featured Speakers For The "Recovery Empowerment Symposium: Emerging From The Storm"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... (NYSE: IBM ) Research has today announced new research ... eye,s retina. The Melbourne based IBM ... abnormalities in retina images, which could in the future offer ... patients who may be at risk of eye diseases – ... developed world. The research began in 2015 ...
(Date:2/21/2017)... NEW YORK , Feb. 21, 2017 /PRNewswire/ ... Read the full report: http://www.reportlinker.com/p04711311-summary/view-report.html ... from COPD and other respiratory diseases. Patients having ... prescribed to use oxygen concentrators. Oxygen concentrators are ... be purchased over the counter. Medical oxygen concentrators ...
(Date:2/21/2017)... 2017   BeyondSpring Pharmaceuticals , a clinical ... innovative immuno-oncology cancer therapies, today announced that the ... Phase 2 trial of BeyondSpring,s innovative lead asset, ... cell lung cancer (NSCLC) with Docetaxel has been ... Clinical Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... ... clinical trial solutions, today announced the further expansion of its eHealth App ... can leverage as part of Bioclinica’s extensive and growing eHealth platform. Applications ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... participants. The connected care demonstration spanned multiple health information systems including OpenEMR, ... 30% of providers have no Health Information Exchange outside of faxing. Medal’s innovative ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... house-caliber protein espresso drinks, announced its products are now available for purchase on ... Protein Drink Mix has become popular among health-conscious consumers who love coffee but ...
(Date:2/20/2017)... ... ... MRI screening improves early diagnosis of breast cancer in all women–not only ... journal Radiology . , MRI has long been known as an effective ... reserve breast MRI screening for women who have a strong family history or other ...
(Date:2/20/2017)... , ... February 20, 2017 , ... Silverado today is ... to open and operate a state-of-the-art memory care community in Alexandria, Virginia. The new ... a site just outside of Old Town. , The three-story community with underground ...
Breaking Medicine News(10 mins):